'Researchers Are Racing to Make a Coronavirus Vaccine. Will It Help?' diff viewer (10/11)

This article is from the source 'nytimes' and was first published or seen on January 29, 2020 00:48 (UTC). It last changed over 40 days ago and won't be checked again for changes.

You can find the current article at its original source at https://www.nytimes.com/2020/01/28/health/coronavirus-vaccine.html

The article has changed 41 times. There is an RSS feed of changes available.

Previous version 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 Next version

Previous version 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 Next version

Version 10	Version 11
Researchers Are Racing to Make a Coronavirus Vaccine. Will It Help?	Researchers Are Racing to Make a Coronavirus Vaccine. Will It Help?
2020-03-20 15:08:20 UTC	2020-06-02 09:18:22 UTC (2 months later)
In the early days of January, as cases of a strange, pneumonia-like illness were reported in China, researchers at the National Institutes of Health in Maryland readied themselves to hunt for a vaccine to prevent the new disease.	In the early days of January, as cases of a strange, pneumonia-like illness were reported in China, researchers at the National Institutes of Health in Maryland readied themselves to hunt for a vaccine to prevent the new disease.
They had clues that a coronavirus, similar to ones that caused the SARS outbreak in 2003 and MERS in 2012, was the culprit. Dr. Barney Graham, deputy director of the Vaccine Research Center at the N.I.H, urged government scientists in China to share the genetic makeup of the virus so his team could begin its race to develop a vaccine.	They had clues that a coronavirus, similar to ones that caused the SARS outbreak in 2003 and MERS in 2012, was the culprit. Dr. Barney Graham, deputy director of the Vaccine Research Center at the N.I.H, urged government scientists in China to share the genetic makeup of the virus so his team could begin its race to develop a vaccine.
On Friday, Jan. 10, the Chinese scientists posted the information on a public database. The next morning, Dr. Graham’s team was in the lab. And within hours, they had pinpointed the letters of the genetic code that could be used to make a vaccine.	On Friday, Jan. 10, the Chinese scientists posted the information on a public database. The next morning, Dr. Graham’s team was in the lab. And within hours, they had pinpointed the letters of the genetic code that could be used to make a vaccine.
Scientists in Australia and at least three companies — Johnson & Johnson, Moderna Therapeutics and Inovio Pharmaceuticals — are also working on vaccine candidates to stop the spread of the disease, which has infected about 6,000 people and killed more than 130.	Scientists in Australia and at least three companies — Johnson & Johnson, Moderna Therapeutics and Inovio Pharmaceuticals — are also working on vaccine candidates to stop the spread of the disease, which has infected about 6,000 people and killed more than 130.
“Everybody is trying to move as quickly as possible,” said Jacqueline Shea, the chief operating officer at Inovio.	“Everybody is trying to move as quickly as possible,” said Jacqueline Shea, the chief operating officer at Inovio.
Inovio received a grant of up to $9 million to develop a coronavirus vaccine from the Coalition for Epidemic Preparedness Innovations, a group whose aim is to speed vaccines to market. Moderna, which is working with Dr. Graham’s team at the N.I.H., received a similar grant, as did researchers at the University of Queensland in Australia.	Inovio received a grant of up to $9 million to develop a coronavirus vaccine from the Coalition for Epidemic Preparedness Innovations, a group whose aim is to speed vaccines to market. Moderna, which is working with Dr. Graham’s team at the N.I.H., received a similar grant, as did researchers at the University of Queensland in Australia.
Historically, vaccines have been one of the greatest public health tools to prevent disease. But even as new technology, advancements in genomics and improved global coordination have allowed researchers to move at unprecedented speed, vaccine development remains an expensive and risky process. It takes months and even years because the vaccines must undergo extensive testing in animals and humans. In the best case, it takes at least a year — and most likely longer — for any vaccine to become available to the public.	Historically, vaccines have been one of the greatest public health tools to prevent disease. But even as new technology, advancements in genomics and improved global coordination have allowed researchers to move at unprecedented speed, vaccine development remains an expensive and risky process. It takes months and even years because the vaccines must undergo extensive testing in animals and humans. In the best case, it takes at least a year — and most likely longer — for any vaccine to become available to the public.
“They may not help in the very early stages of an outbreak, but if we’re able to develop vaccines in time, they will be an asset later,” said Richard Hatchett, the chief executive of the epidemic preparedness coalition.	“They may not help in the very early stages of an outbreak, but if we’re able to develop vaccines in time, they will be an asset later,” said Richard Hatchett, the chief executive of the epidemic preparedness coalition.
With each new outbreak, scientists typically have to start from scratch. After the SARS outbreak in 2003, it took researchers about 20 months from the release of the viral genome to get a vaccine ready for human trials. By the time an epidemic caused by the Zika virus occurred in 2015, researchers had brought the timeline down to six months. Now, they hope the joint efforts will cut that time in half.	With each new outbreak, scientists typically have to start from scratch. After the SARS outbreak in 2003, it took researchers about 20 months from the release of the viral genome to get a vaccine ready for human trials. By the time an epidemic caused by the Zika virus occurred in 2015, researchers had brought the timeline down to six months. Now, they hope the joint efforts will cut that time in half.
The morning after the Chinese scientists published their data earlier this month, Dr. Graham’s team got to work checking the sequence and comparing it with what they already had for SARS and MERS. They wanted to focus on the spike protein, which forms the crown of the coronavirus and recognizes receptors, or entry points, on a host cell.	The morning after the Chinese scientists published their data earlier this month, Dr. Graham’s team got to work checking the sequence and comparing it with what they already had for SARS and MERS. They wanted to focus on the spike protein, which forms the crown of the coronavirus and recognizes receptors, or entry points, on a host cell.
“If you can block the spike protein from binding to a cell, then you’ve effectively prevented an infection,” said Kizzmekia Corbett, the scientific lead for Dr. Graham’s coronavirus team.	“If you can block the spike protein from binding to a cell, then you’ve effectively prevented an infection,” said Kizzmekia Corbett, the scientific lead for Dr. Graham’s coronavirus team.
Dr. Corbett and others had studied the spike proteins on SARS and MERS viruses in detail, using them to develop experimental vaccines. The vaccines never made it to market because SARS was successfully contained with public health measures before the vaccine was ready and preliminary human trials for the MERS vaccine showed success last year.	Dr. Corbett and others had studied the spike proteins on SARS and MERS viruses in detail, using them to develop experimental vaccines. The vaccines never made it to market because SARS was successfully contained with public health measures before the vaccine was ready and preliminary human trials for the MERS vaccine showed success last year.
But the scientists had a method for developing vaccines that could help them fast-track production for the new coronavirus. They used the template for the SARS vaccine and swapped in just enough genetic code that would make it work for the new virus. “I call it plug and play,” Dr. Corbett said.	But the scientists had a method for developing vaccines that could help them fast-track production for the new coronavirus. They used the template for the SARS vaccine and swapped in just enough genetic code that would make it work for the new virus. “I call it plug and play,” Dr. Corbett said.
Within a few hours, Dr. Corbett was able to prepare the modified sequence that the researchers needed. On Tuesday, Jan. 14, the team held a conference call to discuss the next steps with collaborators in labs across the country, and sent off the sequence to Moderna.	Within a few hours, Dr. Corbett was able to prepare the modified sequence that the researchers needed. On Tuesday, Jan. 14, the team held a conference call to discuss the next steps with collaborators in labs across the country, and sent off the sequence to Moderna.
Scientists at the company plan to use the genetic information to create synthetic messenger RNA, which carries instructions for cells’ protein-making machinery. The technology will help induce high levels of antibodies that can identify the spike protein and fight off an infection.	Scientists at the company plan to use the genetic information to create synthetic messenger RNA, which carries instructions for cells’ protein-making machinery. The technology will help induce high levels of antibodies that can identify the spike protein and fight off an infection.
Once Moderna manufactures the messenger RNA in a few weeks, the N.I.H. will run more tests, Dr. Corbett said. Collaborators in academic labs will then test the vaccine in mice infected with the virus and check blood samples from the animals to see how well the experimental vaccine worked.	Once Moderna manufactures the messenger RNA in a few weeks, the N.I.H. will run more tests, Dr. Corbett said. Collaborators in academic labs will then test the vaccine in mice infected with the virus and check blood samples from the animals to see how well the experimental vaccine worked.
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases at the N.I.H., who oversees Dr. Graham’s team, said he expected the vaccine research to move quickly.	Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases at the N.I.H., who oversees Dr. Graham’s team, said he expected the vaccine research to move quickly.
“If we don’t run into any unforeseen obstacles, we’ll be able to get a Phase 1 trial going within the next three months, which will be record speed,” he said, referring to early human trials that test for safety.	“If we don’t run into any unforeseen obstacles, we’ll be able to get a Phase 1 trial going within the next three months, which will be record speed,” he said, referring to early human trials that test for safety.
Other researchers are using different methods to develop their vaccines.	Other researchers are using different methods to develop their vaccines.
Inovio, which is also developing a vaccine for MERS, uses a DNA-based technology. Johnson & Johnson delivers vaccines through adenoviruses — which can cause coldlike symptoms but have been made harmless. And researchers at the University of Queensland are testing particles that mimic the structure of a virus.	Inovio, which is also developing a vaccine for MERS, uses a DNA-based technology. Johnson & Johnson delivers vaccines through adenoviruses — which can cause coldlike symptoms but have been made harmless. And researchers at the University of Queensland are testing particles that mimic the structure of a virus.
	Updated June 1, 2020
	Exercise researchers and physicians have some blunt advice for those of us aiming to return to regular exercise now: Start slowly and then rev up your workouts, also slowly. American adults tended to be about 12 percent less active after the stay-at-home mandates began in March than they were in January. But there are steps you can take to ease your way back into regular exercise safely. First, “start at no more than 50 percent of the exercise you were doing before Covid,” says Dr. Monica Rho, the chief of musculoskeletal medicine at the Shirley Ryan AbilityLab in Chicago. Thread in some preparatory squats, too, she advises. “When you haven’t been exercising, you lose muscle mass.” Expect some muscle twinges after these preliminary, post-lockdown sessions, especially a day or two later. But sudden or increasing pain during exercise is a clarion call to stop and return home.
	States are reopening bit by bit. This means that more public spaces are available for use and more and more businesses are being allowed to open again. The federal government is largely leaving the decision up to states, and some state leaders are leaving the decision up to local authorities. Even if you aren’t being told to stay at home, it’s still a good idea to limit trips outside and your interaction with other people.
	Touching contaminated objects and then infecting ourselves with the germs is not typically how the virus spreads. But it can happen. A number of studies of flu, rhinovirus, coronavirus and other microbes have shown that respiratory illnesses, including the new coronavirus, can spread by touching contaminated surfaces, particularly in places like day care centers, offices and hospitals. But a long chain of events has to happen for the disease to spread that way. The best way to protect yourself from coronavirus — whether it’s surface transmission or close human contact — is still social distancing, washing your hands, not touching your face and wearing masks.
	Common symptoms include fever, a dry cough, fatigue and difficulty breathing or shortness of breath. Some of these symptoms overlap with those of the flu, making detection difficult, but runny noses and stuffy sinuses are less common. The C.D.C. has also added chills, muscle pain, sore throat, headache and a new loss of the sense of taste or smell as symptoms to look out for. Most people fall ill five to seven days after exposure, but symptoms may appear in as few as two days or as many as 14 days.
	If air travel is unavoidable, there are some steps you can take to protect yourself. Most important: Wash your hands often, and stop touching your face. If possible, choose a window seat. A study from Emory University found that during flu season, the safest place to sit on a plane is by a window, as people sitting in window seats had less contact with potentially sick people. Disinfect hard surfaces. When you get to your seat and your hands are clean, use disinfecting wipes to clean the hard surfaces at your seat like the head and arm rest, the seatbelt buckle, the remote, screen, seat back pocket and the tray table. If the seat is hard and nonporous or leather or pleather, you can wipe that down, too. (Using wipes on upholstered seats could lead to a wet seat and spreading of germs rather than killing them.)
	More than 40 million people — the equivalent of 1 in 4 U.S. workers — have filed for unemployment benefits since the pandemic took hold. One in five who were working in February reported losing a job or being furloughed in March or the beginning of April, data from a Federal Reserve survey released on May 14 showed, and that pain was highly concentrated among low earners. Fully 39 percent of former workers living in a household earning $40,000 or less lost work, compared with 13 percent in those making more than $100,000, a Fed official said.
	Yes, but make sure you keep six feet of distance between you and people who don’t live in your home. Even if you just hang out in a park, rather than go for a jog or a walk, getting some fresh air, and hopefully sunshine, is a good idea.
	Taking one’s temperature to look for signs of fever is not as easy as it sounds, as “normal” temperature numbers can vary, but generally, keep an eye out for a temperature of 100.5 degrees Fahrenheit or higher. If you don’t have a thermometer (they can be pricey these days), there are other ways to figure out if you have a fever, or are at risk of Covid-19 complications.
	The C.D.C. has recommended that all Americans wear cloth masks if they go out in public. This is a shift in federal guidance reflecting new concerns that the coronavirus is being spread by infected people who have no symptoms. Until now, the C.D.C., like the W.H.O., has advised that ordinary people don’t need to wear masks unless they are sick and coughing. Part of the reason was to preserve medical-grade masks for health care workers who desperately need them at a time when they are in continuously short supply. Masks don’t replace hand washing and social distancing.
	If you’ve been exposed to the coronavirus or think you have, and have a fever or symptoms like a cough or difficulty breathing, call a doctor. They should give you advice on whether you should be tested, how to get tested, and how to seek medical treatment without potentially infecting or exposing others.
	If you’re sick and you think you’ve been exposed to the new coronavirus, the C.D.C. recommends that you call your healthcare provider and explain your symptoms and fears. They will decide if you need to be tested. Keep in mind that there’s a chance — because of a lack of testing kits or because you’re asymptomatic, for instance — you won’t be able to get tested.
	Charity Navigator, which evaluates charities using a numbers-based system, has a running list of nonprofits working in communities affected by the outbreak. You can give blood through the American Red Cross, and World Central Kitchen has stepped in to distribute meals in major cities.
“We don’t know which vaccine approach will be successful at this stage, so we have to try everything in our arsenal,” said Dr. Gregory Poland, a vaccine expert at the Mayo Clinic in Rochester, Minn.	“We don’t know which vaccine approach will be successful at this stage, so we have to try everything in our arsenal,” said Dr. Gregory Poland, a vaccine expert at the Mayo Clinic in Rochester, Minn.
In interviews, company executives said that partnerships with governments and philanthropic foundations were essential to developing vaccines for outbreaks because there are so many uncertainties.	In interviews, company executives said that partnerships with governments and philanthropic foundations were essential to developing vaccines for outbreaks because there are so many uncertainties.
Dr. Paul Stoffels, Johnson & Johnson’s chief scientific officer, estimated it could take eight to 12 months before his company’s vaccines reach human clinical trials. By then, it is possible the coronavirus outbreak will have been contained. Testing of Johnson & Johnson’s Zika vaccine is currently halted, he said, because new outbreaks of the disease have slowed.	Dr. Paul Stoffels, Johnson & Johnson’s chief scientific officer, estimated it could take eight to 12 months before his company’s vaccines reach human clinical trials. By then, it is possible the coronavirus outbreak will have been contained. Testing of Johnson & Johnson’s Zika vaccine is currently halted, he said, because new outbreaks of the disease have slowed.
“You have to be brave and you have to be a solid company to do this, because there is no real incentive to do this, no financial incentive,” he said.	“You have to be brave and you have to be a solid company to do this, because there is no real incentive to do this, no financial incentive,” he said.
Stéphane Bancel, the chief executive of Moderna, said vaccines were necessary, even if an outbreak wanes, because it could always return. “I think it’s important to be prepared,” he said.	Stéphane Bancel, the chief executive of Moderna, said vaccines were necessary, even if an outbreak wanes, because it could always return. “I think it’s important to be prepared,” he said.